Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Hikma Pharmaceuticals Dividend Announcement
• Hikma Pharmaceuticals announced a semi annually dividend of £24.74 per ordinary share which will be made payable on 2024-09-20. Ex dividend date: 2024-08-15
• Hikma Pharmaceuticals annual dividend for 2024 was £61.92
• Hikma Pharmaceuticals annual dividend for 2023 was £39.73
• Hikma Pharmaceuticals's trailing twelve-month (TTM) dividend yield is 3.37%
• Hikma Pharmaceuticals's payout ratio for the trailing twelve months (TTM) is 55.79%
• Hikma Pharmaceuticals's dividend growth over the last five years (2018-2023) was 16.29% year
• Hikma Pharmaceuticals's dividend growth over the last ten years (2013-2023) was -10.80% year
Hikma Pharmaceuticals Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-08-15 | £24.74 | semi annually | 2024-09-20 |
2024-03-21 | £37.19 | semi annually | |
2023-08-10 | £15.66 | semi annually | 2023-09-15 |
2023-03-23 | £24.08 | semi annually | 2023-05-05 |
2022-08-18 | £16.00 | semi annually | 2022-09-20 |
2022-03-17 | £19.79 | semi annually | 2022-04-28 |
2021-08-19 | £9.50 | semi annually | 2021-09-20 |
2021-03-18 | £17.77 | semi annually | 2021-04-26 |
2020-08-20 | £9.12 | semi annually | 2020-09-21 |
2020-03-19 | £20.83 | semi annually | 2020-05-07 |
2019-08-22 | £11.46 | semi annually | 2019-09-23 |
2019-04-04 | £15.28 | semi annually | 2019-05-22 |
2018-08-23 | £7.31 | semi annually | 2018-09-21 |
2018-04-05 | £11.38 | semi annually | 2018-05-24 |
2017-08-24 | £6.62 | semi annually | 2017-09-22 |
2017-04-06 | £17.68 | semi annually | 2017-05-25 |
2016-09-01 | £6.39 | semi annually | |
2016-04-07 | £10.25 | semi annually | 2016-05-19 |
2015-08-27 | £4.62 | semi annually | 2015-09-25 |
2015-04-16 | £2.55 | semi annually | 2015-05-21 |
2014-08-27 | £144.67 | semi annually | 2014-09-26 |
2014-04-23 | £142.77 | semi annually | 2014-05-22 |
2013-09-04 | £120.25 | semi annually | 2013-10-07 |
2013-04-17 | £4.38 | semi annually | 2013-05-23 |
Hikma Pharmaceuticals Dividend per year
Hikma Pharmaceuticals Dividend growth
Hikma Pharmaceuticals Dividend Yield
Hikma Pharmaceuticals current trailing twelve-month (TTM) dividend yield is 3.37%. Interested in purchasing Hikma Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:
Hikma Pharmaceuticals Financial Ratios
Hikma Pharmaceuticals Dividend FAQ
Other factors to consider when evaluating Hikma Pharmaceuticals as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Hikma Pharmaceuticals stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Hikma Pharmaceuticals's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Hikma Pharmaceuticals publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Hikma Pharmaceuticals distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Hikma Pharmaceuticals are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Hikma Pharmaceuticals sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Hikma Pharmaceuticals distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Hikma Pharmaceuticals declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Hikma Pharmaceuticals's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Hikma Pharmaceuticals's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.